IN DIABETIC NEPHROPATHY
Would-'B' blockbuster? Nephrogenex advances pyridoxamine phase III
By Randy Osborne
Friday, June 20, 2014
Sold as a nutritional supplement before it was ruled a drug by the FDA and went through phase II trials in the hands of Biostratum Inc. pyridoxamine dihydrochloride entered a pivotal program overseen by Nephrogenex Inc., which is testing the derivative of vitamin B6 (pyridoxine) in diabetic nephropathy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.